Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

Novo Nordisk · Phase 3 · Not yet recruiting · Enrollment 352

NCT07622810

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Group A: Bofanglutida (GZR18),n/rn/rn/rn/r
Group B: Semaglutiden/rn/rn/rn/r

Not shown

  • Group A: Bofanglutida (GZR18),: endpoint not reported
  • Group B: Semaglutide: endpoint not reported